BAI Announces 2020 Global Innovation Award Finalists
28.1.2021 16:30:00 EET | Business Wire | Press release
BAI announced the finalists for the 2020 BAI Global Innovation Awards, the industry’s prestigious awards program that celebrates new and innovative solutions in the financial services industry worldwide.
Now in its tenth year, the BAI Global Innovation Awards recognizes leading financial services organizations on a global scale. This year, the awards drew hundreds of nominations from industry leaders demonstrating how their organizations used innovation to tackle their challenges in creative, impactful ways. Each nomination is evaluated by the Innovation Circle, a panel of global financial services innovation leaders who weigh each submission on originality and impact on consumers, employees, communities and the industry to determine the top innovations of the year.
The 2020 BAI Global Innovation Awards finalists are:
Consumer Products of Services Innovation
- Bank Pekao S.A., Poland: PeoPay KIDS
- CaixaBank S.A., Spain: HolaBank – Onboarding + mortgageNow
- FNB Life, South Africa: Dynamic Life – Home
- Meridian Credit Union, Canada: Meridian’s Price Drop
- OneConnect Smart Technology Co., Ltd. (Shenzhen), China: Smart Fast Claim
Customer Experience Innovation
- Bank of Montreal, Canada: BMO AI Cashflow Prediction
- Commonwealth Bank of Australia: Bill Sense
- DBS Bank Ltd, Singapore: DBS Chatbot – Guided Conversation
- Finicity, United States: Empowering the Customer Through Open Banking & Credit Decisioning
- FNB Life, South Africa: We’ve Got You COVI(R)D
Human Capital Innovation
- Citizens Financial Group, United States: Jamie Virtual Career Assistant
- SberBank, Russia: Employee Digital Care Program
- Ziraat Bank, Turkey: Hidden Power of Communication
Internal Process Innovation
- CaixaBank S.A., Spain: The New Mobility Section at Now
- DenizBank, Turkey: Digital Scorecard
- ICICI Bank, India: OPTIMUS – Payment Invoicing and ID Card Issuance System
- OneConnect Smart Technology Co., Ltd. (ShenZhen), China: Smart Contract Cloud Platform
- SberBank, Russia: Contact Center Internal Improvement Process
Marketing Innovation
- Emirates NBD Bank, United Arab Emirates: Emirates NBD Anti-Phishing "It Wasn't Me" Campaign
- imaginTech S.A., Spain: New imagin, a New Way to Communicate
- Synchrony, United States: Millie: A Multi-Channel Personal Finance Platform for Women
RegTech Innovation
- Abu Dhabi Global Market Financial Center (ADGM), United Arab Emirates: ADGM and ClauseMatch collaborate to launch Regulation 2.0
- Fino Payments Bank, India: Enterprise Risk & Fraud Management solution
- KAL ATM Software, Germany: New approach to costly and disruptive ATM hardware upgrades
- Ping An Technology (Shenzhen) Co., Ltd., China: Pingan Beehive Federated Intelligence Platform
Small Business Products or Services Innovation
- Aliasware, Inc., United States: PayVus Small Business Credit Card
- Banco Bradesco, Brazil: Open Banking Initiative: Portal MEI, Solutions for the Individual Micro Entrepreneur
- İşbank, Turkey: TekCap
- RBC Ventures, Canada: Ownr
Societal and Community Impact Innovation
- Citi Ventures Studio, United States: City Builder
- Union Bank of the Philippines: UBX SeekCap
- Woodforest National Bank, United States: Woodforest CEI-Boulos Opportunity Fund
Congratulations to all the finalists of the 2020 BAI Global Innovation Awards. The winners will be announced in February. To learn more please visit BAI Global Innovation Awards.
About BAI
As a nonprofit, independent organization, BAI has delivered the financial services industry’s most actionable insights for more than 95 years, enabling leaders to make smart business decisions every day. We provide in-depth, proprietary research to more than 40 of the top US banks, support more than 2,100 financial services organizations with compliance and professional development training, provide trusted, relevant thought leadership through BAI Banking Strategies reports, podcasts and webinars, and offer specialized events and programs. For more information, visit www.bai.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210128005646/en/
Contact information
Holly Hughes
BAI, Chicago
hhughes@bai.org
+1 (312) 683-2305
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK ® and TRIKAFTA ® , Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 14:30:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported by clinical and/or in vitro data from 564 variants demonstrating response to ALYFTREK and 521 variants demonstrating response to TRIKAFTA. As such, approximately 800 more people with a clinical diagnosis of CF in the U.S. are now eligible for a medicine that treats the underlying cause of their disease for the first time. This extension means approxim
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 14:30:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooperative networks of CCTG, GI Cancer Trials in Australia and France’s Partenariat de Recherche en Oncologie Digestive (PRODIGE) consortium (including Unicancer, GERCOR and FFCD). The BATTMAN (CO.33) trial serves as the registrational-enablin
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 14:19:00 EEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 14:00:00 EEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom